CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 9 No. 8
Pages: 1  2  
Next
 

Current Status of Radiation Sensitization by Fluoropyrimidines

By

Anthony T. Pu, MD, John M. Robertson, MD, and Theodore S. Lawrence, MD, PhD
Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor | August 1, 1995

Numerous clinical studies suggest that the combination of the fluoropyridimine fluorouracil and radiation is a more effective treatment for many cancers, especially gastrointestinal tumors, than is either modality alone. Also, the combination of fluorouracil and radiation has greatly expanded the possibilities for organ-preserving treatments, for example, in patients with bladder cancer. Another fluoropyridimine, floxuridine, administered via the hepatic artery, has been used in combination with irradiation in the treatment of patients with intrahepatic cancers and may prolong survival in patients with unresectable hepatobiliary malignancies. The beneficial effects of combining fluoropyrimidines and radiation are thought to be due to radiosensitization. More studies are needed to clarify the mechanism(s) of radiosensitization so as to optimize regimens in which the fluoropyrimidines are used. [ONCOLOGY 9(8):707-721, 1995]

Introduction

The fluoropyrimidines fluorouracil(Drug information on fluorouracil) (5-FU) and floxuridine (5-fluoro-2'-deoxyuridine, FdUrd [FUDR]) are the most widely used radiation sensitizers in clinical practice. A large number of retrospective and prospective studies have suggested that the combination of fluorouracil and radiation is a more efficacious treatment for many malignancies (particularly gastrointestinal cancers) than either modality alone, and it has been hypothesized that the benefit from this combination is due to radiosensitization. In addition, the related nucleoside floxuridine has been used in combination with low-dose whole liver irradiation and with high-dose partial liver irradiation in the treatment of patients with intrahepatic malignancies.

In this article, we will briefly summarize laboratory studies aimed at determining the mechanism of fluoro- pyrimidine-mediated radiosensitization. (for more detailed reviews, readers are directed to references 1-3). We will then focus on clinical studies demonstrating the efficacy of the combination of radiation and fluoropyrimidines.

Fluoropyrimidine Cytotoxicity

DNA-Mediated Mechanisms

Fluorouracil and floxuridine are analogs of uracil and deoxyuridine, respectively (Figure 1). These compounds are metabolized to form fluorodeoxyuridine monophosphate (FdUMP) (Figure 2), which is ultimately responsible for the DNA-directed effects of both drugs. Fluorodeoxyuridine monophosphate, along with a folate cofactor, binds to and irreversibly inhibits thymidylate synthase (TS), the enzyme responsible for the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Thymidylate synthase inhibition leads to depletion of the product dTMP (and, ultimately, thymidine triphosphate) and to the accumulation of the substrate dUMP and other deoxyuridine nucleotides, particularly deoxyuridine triphosphate (dUTP). The resultant increase in the ratio of dUTP to deoxythymidine triphosphate (dTTP) results in misincorporation of dUTP into DNA. The importance of dUTP levels in cytotoxicity is suggested by the finding that human colon cancer cells transfected with the dUTPase gene, which express increased enzyme activity, are relatively protected from floxuridine cytotoxicity [4].

Prolonged TS inhibition leads ultimately to DNA fragmentation and cell death. Two patterns of DNA fragmentation have been noted. The first involves the production of a wide spectrum of fragments with molecular weights ranging from 50 Kb to 5 Mb, and is associated with a morphologic pattern consistent with necrosis. The second pattern results in discrete fragments weighing between 50 and 200 Kb. It resembles programmed cell death (ie, apoptosis), and suggests that the formation of oligosomal ladders is not an essential part of this phenomenon [5].

RNA-Mediated Mechanisms

Whereas clinically achievable concentrations of floxuridine produce only DNA-mediated cytotoxicity, fluorouracil can also kill cells by RNA-dependent mechanisms. Flurouracil can be metabolized to fluorouracil monophosphate (FUMP) and ultimately to fluorouracil triphosphate (FUTP), which is incorporated into RNA in place of UTP. This misincorporation of FUTP can affect several critical aspects of messenger RNA (mRNA) function (including transcription, translation, and splicing).

The relative importance of DNA- vs RNA-mediated cytotoxicity varies considerably from one cell line to another. Leucovorin can act as a folate cofactor and increase the binding of fluorouracil to TS (see above), which tends to increase fluorouracil's DNA-directed actions.

Fluoropyrimidine-Radiation Interactions

Initial cell culture studies with fluorouracil suggested that sensitization occurred when cells were exposed to cytotoxic drug concentrations after irradiation [1]. Other investigators have studied floxuridine, with its single mode of action rather than the more complex fluorouracil with its RNA- and DNA-directed actions. Floxuridine is a potent radiosensitizer of human colon cancer cells [6,7] (Figure 3). Floxuridine exposure prior to radiation produces significantly greater radiosensitization than treatment after irradiation.

Radiosensitization by floxuridine is related to TS inhibition, and is accompanied by both a decrease in DNA double-strand break [6] and sublethal damage repair [8]. These findings probably also describe fluorouracil-mediated radiosensitization, since it appears to derive from the drug's DNA-directed effects [9]. Also, leucovorin potentiates fluorouracil radiosensitization [2], presumably by increasing TS inhibition.

Various mechanisms have been proposed for fluoropyrimidine-mediated radiosensitization. These include:

  1. Alterations in the nucleotide pools;
  2. Redistribution of cells to a relatively radiosensitive phase of the cell cycle (ie, cells accumulate at the relatively radiosensitive G1/S boundary following exposure to floxuridine); and
  3. Fluorodeoxyuridine triphosphate incorporation into DNA.

Although each of these proposed mechanisms may play a role, none alone explains fluoropyrimidine-radiation interactions.10 Furthermore, recent evidence11 is inconsistent with the hypothesis that cytotoxicity and radio- sensitization are closely correlated [2,12]. We recently proposed that sensitization depends on the inappropriate progression of cells through the G1/S boundary and into S phase during exposure to fluoropyrimidines [10,11]. Research into the mechanisms of fluoropyrimidine-induced cytotoxicity and sensitization is driven by the need to develop methods of overcoming clinical drug resistance.

Pages: 1  2  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Five Steps to Improving Patient Access
Judy Capko,  May 21, 2013
Patient access is getting increased attention through reform initiatives. Here are five steps you can take to make sure patients get appropriate access to care in your office.
Growing HIPAA Threat – Ignore Windows XP at Your Own Peril
Marion K. Jenkins,  May 21, 2013
Chances are good that you have some major ticking software time bombs lurking in your medical practice's computer environment, namely Windows XP and Server 2003.
Finding Physician Work-Life Balance in the Small Moments
Jennifer Frank, MD,  May 21, 2013
At my practice and at home, things are always busy. There's laundry or homework, or a patient with needs.
Three Areas to Reduce Costs at Your Medical Practice
Greg Mertz,  May 19, 2013
By taking a hard look at reducing costs for staffing, overhead, and technology at your medical practice, you may see increased physician compensation.
Dos and Don’ts for Starting a Physician Blog
Michael Woo-Ming, MD,  May 18, 2013
Starting a physician blog can provide your medical practice with marketing benefits, but it's important to do it right.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • “This Is My Last Day on Earth”
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • The ABCDEs of Moles and Melanomas
  • “This Is My Last Day on Earth”
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Bone Metastases
  • Palliative Radiotherapy in Elderly Patients With Bone Metastases Improves Quality of Life
  • Staying Fit Could Ward Off Lung and Colorectal Cancer for Middle-Age Men
  • Obesity Impairs Efficacy of L-Asparaginase in Leukemia Treatment
  • New AUA Guidelines for Prostate Cancer Screening
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Preventing Exposure to Hazardous Drugs
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy